Targeting T-cell Signals for Adult T-cell Leukemia Lymphoma
Inhibition of T-cell Receptor Signaling for Treatment of Adult T-cell Leukemia Lymphoma
This project explores new ways to treat adult T-cell leukemia lymphoma by blocking specific signals within cancer cells.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-11129773 on NIH RePORTER |
What this research studies
Adult T-cell leukemia lymphoma (ATLL) is a very serious blood cancer that is often hard to treat with current methods. Researchers have found that ATLL cells often have changes in a specific communication pathway, called the T-cell receptor (TCR) signaling pathway, which helps the cancer grow. This work aims to understand how these changes drive ATLL and if medicines that target this pathway, like lenalidomide, can work better when combined with standard chemotherapy. The goal is to find more effective treatments for this aggressive disease.
Who could benefit from this research
Good fit: Patients with HTLV-1-associated adult T-cell leukemia lymphoma, particularly those who might be eligible for a Phase 1 clinical trial combining lenalidomide with EPOCH chemotherapy, would be ideal candidates.
Not a fit: Patients without adult T-cell leukemia lymphoma or those whose cancer does not involve the specific T-cell receptor signaling pathway mutations being targeted may not receive direct benefit from this particular approach.
Why it matters
Potential benefit: If successful, this approach could lead to new, more effective treatment options for patients with adult T-cell leukemia lymphoma, potentially improving outcomes where current therapies often fail.
How similar studies have performed: While the specific combination and targeting of this pathway in ATLL is being explored, the concept of targeting specific signaling pathways in cancer has shown success in other types of leukemia and lymphoma.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Ratner, Lee — Washington University
- Study coordinator: Ratner, Lee
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.